{
  "id": 20594584,
  "title": "Sotera Health at Jefferies Global Healthcare Conference: growth stays steady",
  "url": "https://urgent.news/2026/11/18/sotera-health-at-jefferies-global-healthcare-conference-growth-stays",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-18T12:33:19.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/sotera-health-at-jefferies-global-healthcare-conference-growth-stays-steady-93CH-5035811"
  },
  "original_language": "en",
  "account": "On November 18, 2026, Sotera Health presented its business outlook at the Jefferies Global Healthcare Conference. CEO Alton Shader emphasized that the company's sterilization and testing services remain crucial to global healthcare despite some near-term challenges. Sotera's services touch billions of medical products annually across 50 countries. The company remains focused on growing its three existing businesses rather than developing new ones. Net leverage remains within the company's target range of 2x to 3x. The market capitalization of $4.58 billion and P/E ratio of 27.33 suggest the stock is undervalued, with a low PEG ratio of 0.13 indicating strong near-term earnings potential. Sotera's free cash flow has more than doubled since 2020, and it has posted year-over-year revenue growth for 20 consecutive years, even during economic downturns. The Sterigenics unit showed solid third-quarter growth, but some weakness persisted into the fourth quarter. For 2026, constant-currency growth at Sterigenics is expected to be 6%, while companywide EBITDA margins are projected to remain flat. Nelson Labs is expected to carry margins of 30% to 31% in 2026, primarily responsible for the lack of margin expansion this year. The company targets a 50 to 150 basis point EBITDA margin increase over the next few years. Sotera's balance sheet remains solid, with a current ratio of 3.13 and a net leverage of 2.9x. The company's global presence spans three business units, 3,000 associates, 63 facilities, and operations in 13 countries, serving customers in 50 countries. About 70% of revenue from Sterigenics and Nelson Labs comes from shared customers.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}